Thrivent Financial for Lutherans Trims Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Thrivent Financial for Lutherans trimmed its stake in Amedisys, Inc. (NASDAQ:AMED) by 2.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,667 shares of the health services provider’s stock after selling 218 shares during the period. Thrivent Financial for Lutherans’ holdings in Amedisys were worth $740,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMED. KBC Group NV acquired a new position in Amedisys in the third quarter valued at $63,000. Innealta Capital LLC acquired a new stake in shares of Amedisys in the 2nd quarter valued at about $64,000. Signaturefd LLC grew its stake in Amedisys by 88.2% during the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after buying an additional 530 shares during the last quarter. CWM LLC increased its position in Amedisys by 14.5% during the third quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock worth $211,000 after buying an additional 277 shares during the period. Finally, Crossmark Global Holdings Inc. purchased a new stake in Amedisys in the third quarter valued at approximately $243,000. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Stock Performance

Shares of Amedisys stock opened at $86.27 on Wednesday. The firm’s fifty day simple moving average is $94.63 and its 200-day simple moving average is $95.59. Amedisys, Inc. has a 12 month low of $85.84 and a 12 month high of $98.95. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of 34.23, a PEG ratio of 1.92 and a beta of 0.73. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $587.67 million during the quarter, compared to analyst estimates of $586.75 million. During the same quarter in the prior year, the firm posted $0.98 earnings per share. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. As a group, equities analysts forecast that Amedisys, Inc. will post 4.53 earnings per share for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.